The Surfers evaluate a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This high-caliber session offers a plethora of practical considerations around accessing approved NASH pharmacotherapies for those most in need.
Jörn Schattenberg, Louise Campbell, Stephen Harrison and Roger Green share “SurfingNASH predictions” of the most important events that will take place between the 5th and 6th International NASH Days.
The Surfers are joined by Jeff McIntyre of the Global Liver Institute for a thought-provoking session around bringing hepatology to the public health dinner table. This conversation explores what’s going on in the assessment of package nutrition labeling and fighting for fair regulation around what’s deemed “healthy.”
The Surfers are joined by Jeff McIntyre of the Global Liver Institute for a thought-provoking impromptu session on what’s happening thus far for the Fatty Liver field in 2023. They discuss emerging stories in science and policy which elicit responses ranging from positive excitement to head-scratching concern.
In this preview of the Season 2 debut of the Rising Tide series for healthcare professionals who treat diabetic patients, the patients themselves and their caregivers, co-hosts Ken Cusi and Roger Green are joined by Mazen Noureddin to talk about prevalence and taking action on the frontlines today.
This week, SurfingNASH.com is offering conversation previews from our new series, “The NASH Tsunami in Diabetes; Getting Ahead of the Rising Tide.”
This week, SurfingNASH.com is offering conversation previews from our new series, “The NASH Tsunami in Diabetes; Getting Ahead of the Rising Tide.”
In a preview of the premier episode of The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide, key opinion leaders Doctors Stephen Harrison, Kathleen Corey and Kay Pepin join co-hosts Dr. Ken Cusi and Roger Green to discuss key issues related to the NAFLD-Diabetes Link.
The podcast ventures into the emergence of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this final conversation, the panelists provide closing thoughts on the future of this space and how it may play out across different economic systems.
The podcast ventures into the emerging space of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. The panelists consider regulatory challenges for prescribing digital therapeutics as an evidence-based treatment. Additionally, Louise Campbell introduces a free lifestyle app that she is working on that aims to improve liver health.
